Clinical Trials PRRT: From 177Lu to 225Ac: The DOTA-LM3 Antagonist Journey

Disclaimer:
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

The evolution of peptide receptor radionuclide therapy (PRRT) has always been driven by a simple idea: if we can deliver more energy to the tumour while sparing normal tissues, outcomes will improve. For years, the field relied on somatostatin receptor agonists such as DOTATATE. But the emergence of SSTR antagonists—particularly DOTA‑LM3—has reshaped expectations of what PRRT can achieve. LET (Linear Energy Transfer).

Few have been more influential in this shift than Dr Richard P. Baum. His work appears to be ahead of many and the latest news indicates a steady refinement of the LM3 platform: i.e. 177Lu‑LM3 → 161Tb‑LM3 → 225Ac‑LM3. Nonetheless there is no commercial backing for this radioligand at the time of writing.

Note: A hopeful comment by Ronny Allan. While the radioligand LM3 sits without commercial backing, the capability it presents, albeit with multiple individual case studies as the only data, and the ability to deliver tandem PRRT types as one therapy session (alpha emitter and beta emitter), it indicates the potential to improve PRRT capabilities if commercial backing becomes available.

The Antagonist Advantage

Unlike agonists, antagonists like LM3 bind to many more receptor sites, including those not internalised. This leads to:

Higher tumour uptake
Better tumour‑to‑background ratios
Longer tumour retention
Lower renal internalisation (important for α‑emitters)

This makes LM3 an ideal backbone for next‑generation PRRT.

1) 177Lu‑DOTA‑LM3 — Establishing the Foundation

177Lu‑LM3 was the first step in validating the antagonist concept in humans. Dr Baum’s early clinical experience demonstrated:

Higher tumour uptake than 177Lu‑DOTATATE
More binding sites occupied
Excellent tumour‑to‑background ratios
A safety profile comparable to standard 177Lu‑PRRT

This phase was essential: before escalating to higher‑LET emitters, the ligand itself had to prove it behaved predictably and safely.

Readers wanting a deeper dive can explore 177Lu‑LM3.

2) 161Tb‑DOTA‑LM3 — The Precision Upgrade

Once LM3 was validated, the next logical step was to increase LET without dramatically increasing toxicity. Enter 161Tb, a radionuclide that emits:

β‑particles
Auger electrons (ultra‑short‑range, high‑LET)

Clinical and dosimetry studies showed:

Higher absorbed tumour dose than 177Lu‑LM3
Potential superiority for micrometastatic or residual disease
Acceptable toxicity

A note on Auger electrons — and why they are not part of alpha emission

Because 161Tb‑LM3 introduces Auger electrons into the discussion, it’s worth briefly clarifying what they are — and what they are not. Auger electrons are produced when an inner‑shell electron vacancy is filled and the excess energy ejects another electron. This is an atomic relaxation process, not a nuclear one. By contrast, alpha particles are emitted directly from the nucleus as part of alpha decay. In other words, Auger electrons and alpha particles arise from completely different mechanisms. They both deliver very high‑LET damage at extremely short range, but Auger electrons are not part of alpha emission. This distinction explains why 161Tb behaves as a β/Auger hybrid, whereas 225Ac is a true alpha‑emitter with a different therapeutic profile.

More detail: 161Tb‑LM3.

3) 225Ac‑DOTA‑LM3 — The Alpha Leap

The most exciting development in the LM3 programme is the pairing of the antagonist with actinium‑225, a high‑LET α‑emitter capable of delivering lethal DNA damage with only a few hits.

ASCO‑Linked Clinical Output (2026)

Data presented at SNMMI 2026 and discussed in ASCO‑related sessions summarised outcomes from 20 patients treated with 225Ac‑DOTA‑LM3 between 2022–2025.

Patient population

Mostly well‑differentiated G3 NENs
All heavily pre‑treated (177Lu‑DOTATATE, chemotherapy, targeted agents)

Clinical outcomes

1 complete remission
10 partial remissions
2 stable disease
6 progressive disease
Median survival ~18 months in a salvage cohort

For heavily pre‑treated G3 disease, these are highly encouraging signals despite some progressive outcomes

Toxicity

Mostly mild and manageable
Some cytopenias
No unexpected renal toxicity (a key concern for α‑emitters)

Imaging

68Ga‑DOTA‑LM3 PET/CT for baseline and follow‑up
Post‑therapy SPECT/CT confirmed excellent tumour targeting

Is 225Ac‑LM3 Just a Salvage Therapy — Or Something More?

Patient population

The early clinical experience with 225Ac‑DOTA‑LM3 has been concentrated largely in well‑differentiated Grade 3 neuroendocrine neoplasms (G3 NENs). This reflects both clinical reality and trial design: G3 patients often have more aggressive disease biology, fewer durable options after 177Lu‑DOTATATE, and a greater unmet need for high‑LET therapies. As a result, they are frequently prioritised for early access to investigational alpha‑PRRT. The ASCO‑linked cohort was therefore composed mostly of Grade 3 patients, all heavily pre‑treated, making the observed responses — including complete and partial remissions — particularly noteworthy.

At this stage, we simply don’t know what its final place in the treatment sequence would be. What we can say is that the early clinical signals — including the ASCO‑linked experience — suggest that 225Ac‑LM3 may be heading toward a broader role. The LM3 antagonist ligand shows excellent tumour uptake, high receptor occupancy, and favourable retention characteristics, all of which are well‑suited to alpha therapy. If ongoing and future studies confirm safety, durability of response, and reproducibility across centres, 225Ac‑LM3 could evolve from a salvage option into a potentially approved alpha‑PRRT, used earlier in selected patients or integrated into tandem β/α strategies. But first, there needs to be larger trials. This is early days.

This mirrors the trajectory seen in PSMA and GRPR theranostics: prove the ligand → escalate the radionuclide → refine the therapy.

Conclusion: A Platform Still Unfolding but Commercial backing is high risk.

The development of the LM3 antagonist platform is a reminder that progress in theranostics is rarely linear. It evolves through careful iteration, evidence‑building, and the willingness to challenge established assumptions. What began with 177Lu‑LM3 as a proof‑of‑concept has expanded into a multi‑radionuclide strategy that now includes 161Tb and the high‑LET potential of 225Ac. Each step has strengthened the case for LM3 as one of the most versatile and promising ligands in neuroendocrine tumour therapy.

We do not yet know where 225Ac‑DOTA‑LM3 will ultimately sit in the treatment pathway. Its current use in salvage settings reflects regulatory caution rather than biological limitation. The early clinical signals — including the ASCO‑linked experience — suggest that this alpha‑PRRT approach may be heading toward a broader therapeutic role, potentially moving earlier in selected patients or forming part of tandem β/α strategies. What is clear is that LM3 has potentially opened the door to a new generation of high‑LET therapies.

Afterthought – Theranostics – LM3 Tandem Concept

What is tandem PRRT? You will see mention in this blog of “tandem” system which has been explored often using radioligand DOTA‑LM3, a somatostatin receptor antagonist with higher tumour uptake and retention than agonists (e.g., DOTATATE). The tandem concept means administering both isotopes in the same treatment cycle to target heterogeneous tumour volumes. This is clearly very complex but the short answer might be along these lines – Alpha PRRT can fail where beta PRRT still works because alpha particles are extremely short‑range, require very high receptor density, and depend on uniform intratumoral distribution. Beta particles are far more forgiving: they travel further, hit more cells, and can compensate for patchy uptake. Alpha PRRT is better for tiny, dense, high‑uptake disease. Beta PRRT is better for larger, heterogeneous disease.

In addition to the data provided by the LM3 series of trials, you can also click and read this article which focuses exclusively on tandem PRRT treatment using LM3.

Afterthought – Theranostics – LM3 in PET Imaging

LM3 isn’t only a therapeutic antagonist — it now has a growing role in diagnostic PET imaging, giving clinicians a clearer, more sensitive view of SSTR‑positive disease. The same LM3 backbone is paired with different chelators and radionuclides to create tracers optimised for imaging rather than therapy.

LM3 antagonist — The same high‑affinity ligand used in LM3 PRRT as above, offering superior receptor occupancy compared with agonists.
NODAGA chelator — A copper‑compatible chelator that allows LM3 to be labelled with PET‑friendly isotopes.
Cu‑61 — A positron‑emitting radionuclide with a longer half‑life than Ga‑68, enabling flexible imaging logistics and high‑quality PET resolution.
Cu‑61 NODAGA‑LM3 PET/CT — A diagnostic LM3 tracer that could provide antagonist‑based PET imaging, complementing therapeutic LM3 agents such as 177Lu‑LM3, 161Tb‑LM3, and 225Ac‑LM3. Note: The LM3 therapy trial above used 68Ga‑DOTA‑LM3 PET/CT as a follow up.

Why it matters: Cu‑61 NODAGA‑LM3 PET/CT reinforces LM3 as a true theranostic platform — the same ligand can be used to see disease with high sensitivity and then treat it with high‑LET radionuclides. This dual capability strengthens patient selection, improves response assessment, and supports the growing role of LM3 in advanced NET care.

Although Cu‑61 NODAGA‑LM3 PET/CT is part of the same LM3 antagonist family, it was not available for clinical use during the 177Lu‑LM3, 161Tb‑LM3, or 225Ac‑LM3 therapy studies above. At the time those therapies were being delivered, Cu‑61 LM3 was still undergoing its own early clinical evaluation, meaning it could not be used for patient selection or response assessment in therapeutic trials.

As a result, all LM3 therapy cohorts relied on 68Ga‑DOTA‑LM3 PET/CT — the established antagonist PET tracer — for staging, eligibility, dosimetry guidance, and follow‑up. Most likely to ensure regulatory compliance and imaging consistency while Cu‑61 LM3 was still in development.

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.

Finally

Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product. Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document. Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET